Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2016 - 2025)
Zevra Therapeutics' Amortization of Deferred Charges history spans 9 years, with the latest figure at $612000.0 for Q4 2025.
- For Q4 2025, Amortization of Deferred Charges rose 2.0% year-over-year to $612000.0; the TTM value through Dec 2025 reached $2.6 million, up 26.81%, while the annual FY2025 figure was $2.6 million, 26.81% up from the prior year.
- Amortization of Deferred Charges reached $612000.0 in Q4 2025 per ZVRA's latest filing, down from $685000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $779000.0 in Q3 2024 to a low of $142000.0 in Q4 2021.
- Average Amortization of Deferred Charges over 3 years is $503000.0, with a median of $606000.0 recorded in 2024.
- Peak YoY movement for Amortization of Deferred Charges: tumbled 87.94% in 2021, then surged 177.41% in 2025.
- A 3-year view of Amortization of Deferred Charges shows it stood at $142000.0 in 2021, then surged by 322.54% to $600000.0 in 2024, then rose by 2.0% to $612000.0 in 2025.
- Per Business Quant, the three most recent readings for ZVRA's Amortization of Deferred Charges are $612000.0 (Q4 2025), $685000.0 (Q3 2025), and $689000.0 (Q2 2025).